CA
COCP icon

Centerpoint Advisors’s Cocrystal Pharma COCP Stock Holding History

Centerpoint Advisors’s Portfolio COCP Stock Details COCP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-42
Closed -$1K – 255
2018
Q3 		$1K Hold
42
– – ﹤0.01% 225
2018
Q2 		$2K Hold
42
– – ﹤0.01% 292
2018
Q1 		$3K Buy
+42
New +$2.62K ﹤0.01% 195

Other funds holding COCP

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EU
Emory University Atlanta, Georgia $267M AUM 48.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Centerpoint Advisors's COCP Position: Q4 2018 in Review

Centerpoint Advisors sold out of Cocrystal Pharma (COCP) in Q4 2018, closing a stake of 42 shares — an estimated $1K sold.

Centerpoint Advisors first reported a position in COCP in Q1 2018 and held it in 3 quarters. The position peaked at $3K in Q1 2018. 19 funds tracked by Wall St. Rank hold COCP as of Q4 2018.

  • Centerpoint Advisors reported no remaining Cocrystal Pharma position as of Q4 2018 after selling out during the quarter.
  • Centerpoint Advisors sold 42 Cocrystal Pharma shares in Q4 2018, an estimated $1K.
  • Centerpoint Advisors first reported a position in Cocrystal Pharma in Q1 2018 and held it in 3 quarters.
  • Centerpoint Advisors's Cocrystal Pharma position peaked at $3K in Q1 2018.
  • 19 funds tracked by Wall St. Rank held Cocrystal Pharma as of Q4 2018.

Based on Centerpoint Advisors's 13F filing for Q4 2018, filed 5 Feb 2019.